Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view.
Francesco FerraraAndrea ZoviUgo TramaAntonio VitielloPublished in: Inflammopharmacology (2022)
The efforts of the scientific world directed to identifying new antiviral drugs and therapies effective against SARS-CoV-2 continue. New oral antivirals against SARS-CoV-2 such as paxlovid have recently authorized. Evidence shows that these antivirals have good efficacy in reducing the risk of hospitalization in COVID-19 positive patients. Remdesivir is an authorized antiviral for the treatment of SARS-CoV-2 infection. To date, there are still few data in the literature on the safety profile and the risk of generating antiviral-resistant SARS-CoV-2 drug variants. In this manuscript we describe the evidence in the literature on the monotherapy use of paxlovid and monotherapy use of remdesivir, and the scientific hypothesis of using nirmatrelvir and remdesivir in association with the aim of increasing treatment efficacy, reducing the risk of adverse reactions and generating antiviral drug-resistant variants.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- drug resistant
- combination therapy
- systematic review
- multidrug resistant
- coronavirus disease
- end stage renal disease
- copy number
- open label
- acinetobacter baumannii
- clinical trial
- cystic fibrosis
- gene expression
- big data
- dna methylation
- replacement therapy
- artificial intelligence
- patient reported outcomes
- patient reported
- double blind